×
About 10,575 results

ALLMedicine™ Follicular Lymphoma Center

Research & Reviews  4,807 results

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088902
Current Oncology Reports; Longley J, Johnson PWM

May 3rd, 2021 - Epigenetic modifier gene mutations are common in patients with follicular lymphoma. Here we review the pathogenesis of these mutations and how they are targeted by epigenetic drugs including EZH2 inhibitors in both mutated and wild-type disease. T...

A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and H...
https://doi.org/10.1177/10668969211013402
International Journal of Surgical Pathology; Cheng F, Yu F et. al.

May 3rd, 2021 - Histiocytic/dendritic cell tumors are rare in clinical practice. It is postulated that they originate from bone marrow stem cells. Accumulating evidence has established the existence of immunoglobulin gene and T-cell receptor gene rearrangements i...

Reduction of cycles of bendamustine plus rituximab therapy in the cases with good respo...
https://doi.org/10.1002/hon.2871
Hematological Oncology; Takezaki T, Nakazaki K et. al.

May 2nd, 2021 - Bendamusutine plus rituximab (BR) regimen is one of the standard regimens for indolent B-cell lymphomas, yet the possibility of reduction of cycles of BR therapy without compromising therapeutic effects is not still uncovered. We retrospectively s...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

Immune infiltrate diversity confers a good prognosis in follicular lymphoma.
https://doi.org/10.1007/s00262-021-02945-0 10.1200/JCO.2009.26.1693 10.1200/jco.18.02365 10.1182/blood.V130.Suppl_1.412.412 10.1182/blood-2003-12-4434 10.1200/JCO.2008.21.3991 10.1007/s12185-010-0674-x 10.1016/j.beha.2011.02.007 10.3960/jslrt.56.1 10.1182/blood-2005-04-1565 10.1158/1078-0432.CCR-07-0778 10.1200/JCO.2007.12.8298 10.1111/bjh.14201 10.1158/1078-0432.CCR-11-0264 10.1016/j.humpath.2017.03.023 10.1182/blood-2011- 10.1038/bjc.2015.291 10.1182/blood-2006-04-018218.E.C 10.1093/annonc/mdp460 10.1182/blood-2007-11-125823 10.1038/bcj.2015.1 10.1038/s41572-019-0132-x 10.1046/j.1466-822X.2003.00015.x 10.1038/labinvest.2012.91 10.1172/JCI40724 10.1038/labinvest.2014.155 10.1182/blood-2009-07-235598 10.4103/2153-3539.109856 10.3324/haematol.2011.042531 10.1200/JCO.2013.54.8800 10.1177/002215540205001107 10.1097/PAP.0000000000000030 10.2144/01316bt01 10.1038/s41416-019-0634-z 10.1111/j.1365-2141.2011.08942.x 10.1002/hon.2778 10.1200/JCO.2006.10.5833 10.1016/S0167-9473(98)00096-6 10.1136/bmj.332.7549.1080 10.1037/1082-989X.7.1.19 10.1186/s40425-015-0105-x 10.1186/s40425-015-0070-4 10.4161/onci.19545 10.1158/0008-5472.CAN-15-3173 10.1158/0008-5472.CAN-15-1330 10.1097/00001813-200211002-00002 10.1053/hupa.2002.127438 10.3324/haematol.2019.220160 10.1016/j.cell.2015.05.047
Cancer Immunology, Immunotherapy : CII; Tsakiroglou AM, Astley S et. al.

Apr 30th, 2021 - Follicular lymphoma (FL) prognosis is influenced by the composition of the tumour microenvironment. We tested an automated approach to quantitatively assess the phenotypic and spatial immune infiltrate diversity as a prognostic biomarker for FL pa...

see more →

Guidelines  33 results

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for...
https://doi.org/10.1016/j.annonc.2020.11.008
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Ghielmini M et. al.

Nov 29th, 2020 - Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Dreyling M,Ghielmini M,Rule S,Salles G,Ladetto M,|therapeutic use,diagnosis,epidemiology,therapy,diagnosis,therapy,the...

The investigation and management of follicular lymphoma.
https://doi.org/10.1111/bjh.16872
British Journal of Haematology; McNamara C, Montoto S et. al.

Jun 24th, 2020 - The investigation and management of follicular lymphoma.|2020|McNamara C,Montoto S,Eyre TA,Ardeshna K,Burton C,|diagnosis,therapy,

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

May 31st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 29th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. T...

Novel CAR-T Cell Therapy Combination Shows Preliminary Activity in R/R B-cell Lymphoma
https://www.targetedonc.com/view/novel-car-t-cell-therapy-combination-shows-preliminary-activity-in-r-r-b-cell-lymphoma

May 28th, 2020 - First-in-human findings show that ALLO-501, an allogeneic chimeric antigen receptor (CAR)-T cell therapy plus ALLO-647, a monoclonal antibody, has clinical activity and is tolerable in patients with relapsed/refractory large B-cell or follicular l...

see more →

Drugs  23 results see all →

Clinicaltrials.gov  5,217 results

Expert Point of View: Peter Martin, MD
https://ascopost.com/issues/may-10-2021/epov-peter-martin/

May 9th, 2021 - “With current therapies, the median survival for people with follicular lymphoma [FL] is about 20 years. Most people with FL will live as long as the general population, as it is a disease of morbidity more than mortality. That said, there is stil...

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088902
Current Oncology Reports; Longley J, Johnson PWM

May 3rd, 2021 - Epigenetic modifier gene mutations are common in patients with follicular lymphoma. Here we review the pathogenesis of these mutations and how they are targeted by epigenetic drugs including EZH2 inhibitors in both mutated and wild-type disease. T...

A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and H...
https://doi.org/10.1177/10668969211013402
International Journal of Surgical Pathology; Cheng F, Yu F et. al.

May 3rd, 2021 - Histiocytic/dendritic cell tumors are rare in clinical practice. It is postulated that they originate from bone marrow stem cells. Accumulating evidence has established the existence of immunoglobulin gene and T-cell receptor gene rearrangements i...

Reduction of cycles of bendamustine plus rituximab therapy in the cases with good respo...
https://doi.org/10.1002/hon.2871
Hematological Oncology; Takezaki T, Nakazaki K et. al.

May 2nd, 2021 - Bendamusutine plus rituximab (BR) regimen is one of the standard regimens for indolent B-cell lymphomas, yet the possibility of reduction of cycles of BR therapy without compromising therapeutic effects is not still uncovered. We retrospectively s...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

see more →

News  493 results

EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
https://www.medscape.com/viewarticle/948269

Mar 28th, 2021 - European Union approval has been recommended for duvelisib (Copiktra) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or refractory follicular lymphoma (FL) who have received at least two prior lines of therapy. The Europe...

FDA Approves Umbralisib (Ukoniq) for Two Lymphomas
https://www.medscape.com/viewarticle/945426

Feb 7th, 2021 - The US Food and Drug Administration (FDA) has granted accelerated approval to umbralisib (Ukoniq) for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and...

First Data for CAR T-cell Therapy in Follicular Lymphoma: ZUMA-5
https://www.medscape.com/viewarticle/942494

Dec 10th, 2020 - For the first time, a chimeric antigen receptor (CAR) therapy has yielded a high response rate among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), including patients with follicular lymphoma (FL) and marginal zone lymphom...

First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers
https://www.staging.medscape.com/viewarticle/939347

Oct 18th, 2020 - Tazemetostat (Tazverik) showed potential for improving outcomes for patients with advanced or metastatic epithelioid sarcoma and also yielded clinically meaningful responses in heavily pretreated patients with follicular lymphoma. The findings com...

First-in-Class Oral EZH2 Inhibitor Effective in Two Cancers
https://www.medscape.com/viewarticle/939347

Oct 18th, 2020 - Tazemetostat (Tazverik) showed potential for improving outcomes for patients with advanced or metastatic epithelioid sarcoma and also yielded clinically meaningful responses in heavily pretreated patients with follicular lymphoma. The findings com...

see more →

Patient Education  2 results see all →